Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about HDAC3: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
HDAC3 is a gene implicated in neurodegeneration research. Key relationships include: regulates, activates, associated with. Associated with Aging, Als, Alzheimer. Connected to 124 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | HDAC3 |
| Full Name | Histone Deacetylase 3 |
| Chromosome | 5q31.3. |
| Protein Type | Epigenetic Regulator |
| Target Class | Epigenetic Regulator |
| Function | HDAC3 encodes histone deacetylase 3, a class I histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histone proteins. |
| Mechanism of Action | Small molecule inhibitor of histone deacetylase enzymatic activity |
| Primary Expression | Ubiquitous with highest expression in brain |
| Druggability | Low (0.41) |
| Clinical Stage | Approved |
| Molecular Weight | 33 kDa |
| Amino Acids | 428 aa |
| Pathways | Autophagy, Epigenetic, Memory, Neuroprotection, Oxidative Stress |
| UniProt ID | O15379 |
| Ensembl ID | ENSG00000171720 |
| OMIM | 605166 |
| GeneCards | HDAC3 |
| Human Protein Atlas | HDAC3 |
| Associated Diseases | AGING, ALS, Alzheimer, Alzheimer's disease |
| Known Drugs/Compounds | acetate, Acetate, GS-1, H3K9, Kaempferol, MELATONIN |
| Interactions | ABCA1, AGING, AKT, ALZHEIMER, ALZHEIMER'S DISEASE, AMPA RECEPTOR |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Selective HDAC3 Inhibition with Cognitive Enhancem HDAC3-Selective Inhibition for Clock Reset HDAC3-Dependent A1 Astrocyte Commitment Window |
| KG Connections | 1064 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
HDAC3["HDAC3"]
HDAC3 -->|"target for"| neurodegeneration["neurodegeneration"]
HDAC3 -->|"contributes to"| Neurodegeneration["Neurodegeneration"]
HDAC3 -->|"regulates"| Parkinson["Parkinson"]
HDAC3 -->|"regulates"| Alzheimer["Alzheimer"]
HDAC3 -->|"regulates"| Neuroinflammation["Neuroinflammation"]
HDAC3 -->|"regulates"| Inflammation["Inflammation"]
HDAC3 -->|"regulates"| Huntington["Huntington"]
HDAC3 -->|"regulates"| Ms["Ms"]
HDAC3 -->|"activates"| Anxiety["Anxiety"]
h_a9571dbb["h-a9571dbb"] -->|"target for"| HDAC3
h_0e675a41["h-0e675a41"] -->|"target for"| HDAC3
SIRT6["SIRT6"] -->|"regulates"| HDAC3
HDAC11["HDAC11"] -->|"expressed in"| HDAC3
HDAC2["HDAC2"] -->|"expressed in"| HDAC3
SIRT7["SIRT7"] -->|"regulates"| HDAC3
SIRT5["SIRT5"] -->|"regulates"| HDAC3
BDNF["BDNF"] -->|"regulates"| HDAC3| Target | Relation | Type | Str |
|---|---|---|---|
| HDAC3 | encodes | protein | 0.00 |
| Brain Development | regulates | process | 0.95 |
| endothelial cell metabolic reprogramming | drives | process | 0.95 |
| Nlrp3 Inflammasome | promotes | process | 0.95 |
| Neurodegeneration | regulates | process | 0.95 |
| Alzheimer'S Disease | associated_with | disease | 0.95 |
| neural stem cells | regulates | cell_type | 0.90 |
| neural stem cells | activates | cell_type | 0.90 |
| diabetic retinopathy | involved_in | disease | 0.90 |
| Memory Formation | regulates | process | 0.90 |
| histone acetylation | suppresses | process | 0.90 |
| tumorigenesis | promotes | process | 0.90 |
| mitochondrial fission | promotes | process | 0.90 |
| NLRP3 | associated_with | protein | 0.90 |
| Nrf2 Signaling Pathway | mediates | pathway | 0.90 |
| NRF2 | regulates | gene | 0.90 |
| Pro-Inflammatory Cytokines | regulates | protein | 0.90 |
| Tumor Progression | involved_in | process | 0.90 |
| neural stem cells | inhibits | cell_type | 0.90 |
| epigenetic regulation | participates_in | pathway | 0.90 |
| H3K9 | modulates | compound | 0.88 |
| inflammation | promotes | process | 0.88 |
| Axonogenesis | modulates | process | 0.85 |
| Neurogenesis | modulates | process | 0.85 |
| 8-Cell Embryo Development | expressed_in | process | 0.85 |
| Cognitive Impairment | regulates | phenotype | 0.85 |
| transcriptional regulation | regulates | process | 0.85 |
| oocyte maturation | regulates | process | 0.85 |
| signaling pathways | modulates | pathway | 0.85 |
| somatic cell nuclear transfer | involved_in | process | 0.82 |
| Nf-Κb Pathway | regulates | pathway | 0.82 |
| Kaempferol | targets | compound | 0.82 |
| synaptic plasticity | participates_in | pathway | 0.80 |
| NLRP3 inflammasome | activates | pathway | 0.80 |
| cortex | expressed_in | brain_region | 0.80 |
| unfolded protein response | participates_in | pathway | 0.80 |
| microglia | activates | cell_type | 0.80 |
| neurons | inhibits | cell_type | 0.80 |
| neural stem cells | associated_with | cell_type | 0.80 |
| BDNF | represses | gene | 0.80 |
| cloned embryo development | regulates | process | 0.80 |
| Neuropsychiatric Disorders | therapeutic_target | disease | 0.80 |
| Neurodevelopmental Disorders | therapeutic_target | disease | 0.80 |
| memory loss | causes | phenotype | 0.80 |
| Neurodegenerative Disorders | therapeutic_target | disease | 0.80 |
| H3K27_acetylation | deacetylates | histone_mark | 0.80 |
| acetate | regulates | compound | 0.75 |
| Als | activates | disease | 0.75 |
| Somatic Cell Nuclear Transfer | involved_in | process | 0.75 |
| neurodegeneration | therapeutic_target | disease | 0.73 |
| Source | Relation | Type | Str |
|---|---|---|---|
| HDAC3 | encodes | gene | 0.00 |
| Rgfp966 | inhibits | drug | 0.95 |
| GS-1 | degrades | compound | 0.95 |
| GS-1 | binds | compound | 0.92 |
| h-0e675a41 | targets | hypothesis | 0.90 |
| h-a9571dbb | targets | hypothesis | 0.90 |
| MIR34A | downregulates | gene | 0.90 |
| SATB2 | interacts_with | protein | 0.90 |
| Riboflavin | downregulates | drug | 0.88 |
| riboflavin | downregulates | compound | 0.85 |
| Acetate | interacts_with | compound | 0.85 |
| hypoxia | upregulates | process | 0.85 |
| HSV-gB | upregulates | protein | 0.85 |
| Kaempferol | targets | compound | 0.85 |
| acetate | activates | compound | 0.80 |
| GABA | inhibits | gene | 0.80 |
| C-Phycocyanin | downregulates | compound | 0.80 |
| GS-1 | targets | gene | 0.80 |
| circadian_rhythm | regulated_by | process | 0.80 |
| MELATONIN | activates | drug | 0.70 |
| NLRP3 | interacts_with | gene | 0.70 |
| AGING | treats | phenotype | 0.70 |
| MELATONIN | inhibits | drug | 0.70 |
| TAU | treats | protein | 0.70 |
| MACROPHAGE | exacerbates | cell_type | 0.70 |
| BDNF | associated_with | gene | 0.65 |
| ALZHEIMER | associated_with | gene | 0.65 |
| APOPTOSIS | associated_with | gene | 0.65 |
| AKT | associated_with | gene | 0.65 |
| DEMENTIA | associated_with | gene | 0.65 |
| BDNF | targets | gene | 0.65 |
| HDAC2 | associated_with | gene | 0.65 |
| AMYLOID | associated_with | gene | 0.65 |
| ABCA1 | associated_with | gene | 0.65 |
| HDAC1 | associated_with | gene | 0.65 |
| AUTOPHAGY | associated_with | gene | 0.65 |
| NLRP3 INFLAMMASOME | degrades | pathway | 0.65 |
| GALANTAMINE | regulates | drug | 0.65 |
| METASTASIS | regulates | phenotype | 0.65 |
| INFLAMMATION | inhibits | gene | 0.60 |
| APOPTOSIS | inhibits | gene | 0.60 |
| BCL-2 | inhibits | gene | 0.60 |
| NF-ΚB | inhibits | gene | 0.60 |
| SRC | activates | gene | 0.60 |
| AGING | activates | gene | 0.60 |
| MITOPHAGY | activates | gene | 0.60 |
| HDAC | activates | gene | 0.60 |
| CYTOKINES | activates | gene | 0.60 |
| STAT3 | activates | gene | 0.60 |
| NRF2 | protects_against | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Selective HDAC3 Inhibition with Cognitive Enhancement | 0.779 | neurodegeneration | Epigenetic reprogramming in aging neuron |
| HDAC3-Selective Inhibition for Clock Reset | 0.710 | neurodegeneration | Epigenetic clocks and biological aging i |
| Butyrate-Producing Commensal Depletion Creates Vicious Cycle | 0.630 | neurodegeneration | How does gut microbiome dysbiosis contri |
| CX3CR1-Targeted HDAC3 Knockdown in Microglia via AAV9 Delive | 0.620 | pharmacology | How can CNS-selective HDAC/DNMT inhibito |
| HDAC3-Dependent A1 Astrocyte Commitment Window | 0.611 | neurodegeneration | What is the optimal therapeutic window d |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-04 | 9 hypotheses Top: 0.937
neurodegeneration | 2026-04-01 | 6 hypotheses Top: 0.710
neurodegeneration | 2026-04-01 | 5 hypotheses Top: 0.720
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Epigenetic clocks association with brain aging patterns in older women | exploratory | cognitive impairment and demen | 0.900 | 0.00 | human patients | proposed | N/A |
| Proposed experiment from debate on Epigenetic clocks and biological ag | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Animal Model Comparison for Neurodegenerative Disease Therapeutics | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Epigenetic Dysregulation in Huntington's Disease — Therapeutic Targeti | validation | Neurodegeneration | 0.400 | 0.50 | human | completed | $3,000,000 |
| Epigenetic Dysregulation Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disea | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Proposed experiment from debate on Microglia activate astrocytes via I | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| CRISPR Gene Correction Approaches for CBS/PSP | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Effect of Electronic Prescribing Compared to Paper-Based (Handwritten) Prescribi [PMID:34433219] | Aluga D, Nnyanzi LA, King N, Okolie EA, | Appl Clin Inform | 2021 | 1 |
| Structurally diverse sesquiterpenoids from the aerial parts of Artemisia annua ( [PMID:32891001] | Qin DP, Li HB, Pang QQ, Huang YX, Pan DB | Bioorg Chem | 2020 | 1 |
| Mycobacterium Abscessus: A Rare Cause of Peri-Ductal Mastitis in Endemic Regions [PMID:32580856] | Shaikh A, Vohra LM | J Coll Physicians Surg Pak | 2020 | 1 |
| The scanning ion conductance microscope for cellular physiology. [PMID:23086993] | Lab MJ, Bhargava A, Wright PT, Gorelik J | Am J Physiol Heart Circ Physio | 2013 | 1 |
| Telomere dysfunction causes sustained inflammation in chronic obstructive pulmon [PMID:21885626] | Amsellem V, Gary-Bobo G, Marcos E, Maitr | Am J Respir Crit Care Med | 2011 | 1 |
| Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's diseas [PMID:21102463] | Franke A, McGovern DP, Barrett JC, Wang | Nat Genet | 2010 | 1 |
| HDAC3 Preserves the primordial follicle reserve by epigenetically suppressing fe [PMID:41803516] | ["Chen Z", "Guo J", "Gao M", "Wang H", " | Cellular and molecular life sc | 2026 | 0 |
| Determination of the effects of [PMID:41823023] | ["Yir\u00fcn A", "\u00c7ak\u0131r D", "E | Journal of Alzheimer's disease | 2026 | 0 |
| Discovery of a Covalent HDAC3 Degrader with Excellent Anti-Inflammatory Activity [PMID:41812251] | ["Qin H", "Shi Y", "Liu R", "Wang B", "G | Journal of medicinal chemistry | 2026 | 0 |
| Myeloid HDAC3 deletion protects against traumatic optic injury. [PMID:41851071] | Shahror RA, Morris CA, Cunningham A, Chu | Cell death discovery | 2026 | 0 |
| HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis [PMID:41023273] | Mitchell CD, Morris CA, Wild M, Cunningh | Acta Pharmacol Sin | 2026 | 0 |
| Metabolomics identifies riboflavin as a therapeutic agent for acute pancreatitis [PMID:41352543] | Shi Y, Peng J | J Nutr Biochem | 2026 | 0 |
| β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708] | Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et | Acta Pharmacol Sin | 2026 | 0 |
| SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibi [PMID:41736683] | Wen T, Yang L, Cai S, Liu Y, Fan J et al | Adv Sci (Weinh) | 2026 | 0 |
| Histone deacetylases: Function in tumor development and therapeutic prospects (R [PMID:41783166] | Lin R, Zhang Y, Li H, Liang F | Oncol Lett | 2026 | 0 |
| LncRNA SNHG5 promotes macrophage lipid accumulation and aggravates atheroscleros [PMID:41844502] | Liu X, Wang HH, Lan XY, Sun SY, Xu XD, H | Biochimica et biophysica acta. | 2026 | 0 |
| HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable [PMID:41912135] | Jiang Y, Cheng S, Zhang CY, Jin X, Li L, | Cancer letters | 2026 | 0 |
| Histone Deacetylases Are Required for Aedes aegypti Female Reproduction and Embr [PMID:41764745] | ["Balasubramani S", "Palli S"] | Archives of insect biochemistr | 2026 | 0 |
| Microglial HDAC3 inhibits the migration of CD8-positive T cell in the developmen [PMID:41888851] | Na Che; Yang Zhang; Bo Wang; Hongxing Wu | Cell & bioscience | 2026 | 0 |
| GR/HDAC3 Regulates Npas4 Signaling Pathway and Mediates Cognitive Impairment in [PMID:41837847] | Zhao Z, Song Y, Yu X, Gao Q, Wang B, Sun | FASEB journal : official publi | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.82 · 2026-04-22
closed · Rounds: 4 · Score: 0.95 · 2026-04-10
closed · Rounds: 4 · Score: 0.93 · 2026-04-06
Hypotheses and analyses mentioning HDAC3 in their description or question text
No additional research found